Dry age-related macular degeneration is an eye condition that typically develops gradually, affecting millions of older adults worldwide. While there is currently no cure that restores lost vision, understanding the available approaches to slow progression, manage symptoms, and maintain quality of life can help patients and their families navigate this challenging diagnosis with greater confidence.

How Medical Care Aims to Preserve Your Vision

When someone learns they have dry age-related macular degeneration, often called dry AMD, the primary goal of care shifts to slowing down the deterioration of the macula—the central part of the eye’s retina responsible for sharp, straight-ahead vision. Unlike some eye conditions where surgery or medication can reverse damage, dry AMD requires a different mindset: preserving what vision remains and adapting to changes as they occur.^[1]

The approach to managing dry AMD varies significantly depending on how far the condition has progressed. In the early stages, when tiny yellow protein deposits called drusen begin forming beneath the macula but vision remains largely intact, the focus is on prevention and monitoring. As the disease moves into intermediate stages, where some people start noticing mild blurriness or difficulty seeing in dim light, more active intervention through nutritional support becomes important. In the late or advanced stage, which can include a severe form called geographic atrophy where patches of retinal tissue waste away, newer treatments are starting to emerge alongside low vision rehabilitation services.^[2][6]

The reality that standard treatments approved by medical societies have been limited creates both frustration and hope. While doctors previously had little to offer beyond lifestyle advice and vitamin supplements, ongoing research into new therapies—including clinical trial drugs—is beginning to change this landscape. Understanding what’s currently available and what’s being tested helps patients make informed decisions about their care.^[11]

Standard Treatment Approaches for Dry AMD

For many years, the cornerstone of managing dry age-related macular degeneration has centered on nutritional supplementation rather than prescription medications. The landmark Age-Related Eye Disease Study, commonly known as AREDS, followed by the updated AREDS2 study, demonstrated that specific combinations of vitamins and minerals could slow the progression of intermediate dry AMD to advanced stages. This research fundamentally changed how ophthalmologists approach the condition, even though these supplements don’t cure the disease or restore vision that’s already been lost.^[3][16]

The AREDS2 formula typically includes vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. These nutrients work together to support the health of retinal cells and may help protect against oxidative damage that contributes to macular deterioration. Doctors generally recommend this combination for people with intermediate dry AMD or those who have advanced AMD in one eye but not the other. The therapy doesn’t require a prescription in most cases, though consultation with an eye care professional ensures the right formulation and dosage for individual circumstances.^[6][13]

Beyond supplementation, lifestyle modifications play a crucial supporting role. Smoking cessation ranks among the most important actions anyone with dry AMD can take, as smoking significantly accelerates disease progression and increases the risk of advancing to late-stage AMD. The harmful effects of tobacco on retinal blood vessels and overall eye health are well documented, making quitting one of the most impactful interventions available.^[3][5]

Diet also matters considerably. Eating foods rich in leafy green vegetables, fish high in omega-3 fatty acids, and colorful fruits and vegetables provides natural sources of the same nutrients found in AREDS2 supplements. While dietary intake alone may not match supplement levels, a healthy eating pattern supports overall eye health and general wellbeing. Some patients find that combining both approaches—eating well and taking supplements—gives them a sense of actively participating in their care.^[20][21]

Regular monitoring through comprehensive eye examinations allows ophthalmologists to track disease progression and adjust recommendations accordingly. These visits typically include dilated eye exams where the doctor examines the back of the eye for drusen accumulation and signs of atrophy. Additional imaging tests such as optical coherence tomography (OCT) create detailed cross-sectional pictures of the retina, revealing changes in retinal layers that aren’t visible during standard examination. Some patients also use an Amsler grid at home—a simple pattern of straight lines—to monitor their central vision for distortions that might signal progression.^[9][19]

Protective measures against environmental factors round out standard care recommendations. Wearing sunglasses that block ultraviolet and blue light when outdoors may help shield the eyes from potentially damaging radiation. Managing other health conditions such as high blood pressure, high cholesterol, and maintaining a healthy weight also contributes to better outcomes, as cardiovascular health and eye health are interconnected.^[6][16]

The duration of these standard treatments is essentially indefinite—people typically continue taking AREDS2 supplements and maintaining healthy habits for the rest of their lives. This long-term commitment can feel overwhelming at first, but many patients report that establishing routines makes it manageable. Side effects from AREDS2 supplements are generally minimal, though some people experience digestive upset or yellowing of skin from high zinc doses. Discussing any concerns with a healthcare provider can help adjust formulations when needed.^[3]

Emerging Treatments in Clinical Research

The landscape of dry AMD treatment shifted dramatically in 2023 when the U.S. Food and Drug Administration approved pegcetacoplan, marketed as Syfovre, specifically for geographic atrophy—the advanced form of dry AMD. This marked the first time a treatment beyond nutritional supplementation received regulatory approval for this condition. Pegcetacoplan is an injection given directly into the eye that works by targeting part of the body’s complement system, a component of the immune response believed to contribute to retinal damage in geographic atrophy.^[12]

Clinical trials demonstrated that Syfovre could slow the growth of geographic atrophy lesions, potentially helping patients retain vision longer than would occur naturally. The treatment requires regular injections—typically every 25 to 60 days depending on the dosing schedule—administered in an ophthalmologist’s office. While this frequent treatment schedule presents challenges, it represents a significant breakthrough for people with advanced dry AMD who previously had no medical options beyond low vision aids.^[12]

Another medication that received FDA approval shortly after Syfovre is avacincaptad pegol, sold under the brand name Izervay. This drug also targets the complement system but through a slightly different mechanism. Like pegcetacoplan, it’s delivered through eye injections and aims to slow geographic atrophy progression. Both treatments are currently approved only for geographic atrophy, not earlier stages of dry AMD, meaning many patients must wait until their condition advances before becoming eligible.^[11][12]

Researchers are exploring numerous other therapeutic approaches in various phases of clinical testing. Some investigational treatments focus on protecting retinal cells from dying through neuroprotective mechanisms. Others attempt to clear away drusen deposits or reduce inflammation in the retina. Gene therapy approaches are being studied to deliver protective genes to retinal cells, potentially offering long-term benefit from a single treatment or fewer repeat procedures.^[11]

Stem cell therapy represents another frontier in AMD research. Scientists are investigating whether transplanting healthy retinal cells grown from stem cells could replace damaged tissue in the macula. This approach remains largely experimental, with ongoing clinical trials examining safety and early signals of effectiveness. If successful, stem cell transplantation might one day restore some lost vision rather than simply slowing further decline—a goal that would transform how we think about treating dry AMD.^[13]

Clinical trials for dry AMD treatments occur at medical centers throughout the United States, Europe, and other regions. Eligibility typically depends on disease stage, with many studies specifically enrolling people with intermediate dry AMD or geographic atrophy. Some trials have specific requirements about visual acuity levels, the size and location of drusen or atrophic areas, and whether one or both eyes are affected. Patients interested in participating can ask their ophthalmologist about nearby trials or search clinical trial databases for studies accepting volunteers.^[11]

Understanding the different phases of clinical trials helps set realistic expectations. Phase I trials focus primarily on safety, testing new treatments in small groups to identify potential side effects and determine appropriate dosing. Phase II trials expand to larger groups and begin examining whether the treatment shows promise for slowing disease progression or improving outcomes. Phase III trials compare the new treatment directly against current standard care in even larger patient populations, providing the strongest evidence about effectiveness. Drugs that successfully complete Phase III trials may then seek regulatory approval.^[11]

Preliminary results from ongoing research suggest several promising directions. Some investigational drugs have shown the ability to reduce drusen volume or slow the rate of geographic atrophy expansion in Phase II studies. Others demonstrate good safety profiles with fewer side effects than initially anticipated. However, it’s crucial to remember that many treatments that seem promising in early trials ultimately don’t prove effective in larger studies. The path from laboratory discovery to approved medication is long and uncertain, requiring patience from both researchers and patients hoping for new options.^[11]

Gene therapy approaches under investigation include delivering genes that produce protective proteins or reduce harmful inflammatory responses in the retina. These treatments typically involve a single injection into the eye that could potentially provide benefit for months or years, reducing the burden of frequent repeat treatments. Early-phase trials are examining safety and optimal delivery methods, with results expected to guide whether these approaches advance to larger efficacy studies.^[11]

Research into combination therapies is also underway, testing whether using multiple treatments together might work better than any single approach alone. For example, pairing a drug that slows geographic atrophy with nutritional supplements that support overall retinal health could potentially provide additive benefits. These complex studies require careful design to understand how different interventions interact.^[11]

Most Common Treatment Methods

• Nutritional Supplementation
  • AREDS2 formula containing vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin, recommended for intermediate dry AMD
  • Taken daily as part of long-term management strategy
  • Shown in clinical studies to slow progression from intermediate to advanced stages
  • Generally well-tolerated with minimal side effects^[3][13]
• Complement Inhibitor Injections
  • Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) approved for geographic atrophy
  • Delivered through regular eye injections every 4 to 8 weeks
  • Work by blocking part of the immune system’s complement pathway
  • Demonstrated ability to slow growth of atrophic lesions in clinical trials^[12]
• Lifestyle Modifications
  • Smoking cessation to reduce risk of disease progression
  • Diet rich in leafy greens, fish, and colorful vegetables
  • Regular exercise and weight management
  • Blood pressure and cholesterol control
  • Sun protection through UV-blocking sunglasses^[20][21]
• Vision Monitoring and Rehabilitation
  • Regular eye examinations with dilated pupil examination
  • Optical coherence tomography (OCT) imaging to track retinal changes
  • Home monitoring using Amsler grid to detect vision changes
  • Low vision rehabilitation services and assistive devices for advanced stages
  • Occupational therapy to learn adaptive strategies for daily tasks^[17][18]
• Experimental Therapies in Clinical Trials
  • Gene therapy approaches delivering protective genetic material
  • Stem cell transplantation to replace damaged retinal tissue
  • Novel anti-inflammatory medications
  • Neuroprotective drugs to prevent retinal cell death
  • Combination treatment approaches^[11][13]

Living Well Despite Vision Changes

Even as medical treatments work to slow disease progression, learning to adapt to vision changes remains essential for maintaining independence and quality of life. Visual rehabilitation—a specialized field that helps people maximize their remaining vision—offers practical strategies that many patients find transformative. These services don’t require a prescription medication but do require commitment to learning new ways of accomplishing familiar tasks.^[17]

Low vision specialists, occupational therapists trained in vision rehabilitation, and orientation and mobility instructors work together to assess individual needs and recommend specific adaptations. This might include magnifying devices for reading, special lighting arrangements that reduce glare while increasing contrast, or electronic aids that enlarge text or convert written material to speech. Many people discover that relatively simple adjustments—like using a black pen instead of blue, marking appliance settings with raised tactile dots, or rearranging furniture to improve lighting—make daily activities considerably easier.^[18]

Because dry AMD affects central vision while leaving peripheral or side vision intact, patients learn to use their remaining vision strategically. This might involve looking slightly to the side of an object rather than directly at it, a technique called eccentric viewing that takes advantage of healthier retinal areas outside the damaged macula. While this feels awkward initially, many people become quite skilled with practice and training.^[17]

Technology offers increasingly sophisticated tools for people with vision impairment. Smartphones and tablets include built-in accessibility features like screen magnification, high-contrast displays, and voice control. E-readers allow users to adjust text size and background color for maximum readability. Video magnifiers provide powerful enlargement of printed materials, photographs, and craft projects. Audio books and podcasts offer entertainment and information when reading becomes too challenging. Learning to use these technologies opens up possibilities that help people stay connected and engaged.^[18]

The emotional impact of vision loss deserves attention equal to the physical aspects. Many people with dry AMD experience anxiety, frustration, grief, or depression as they adapt to changing abilities. These feelings are normal responses to a significant life change. Support groups—whether meeting in person or online—connect people with others who understand the unique challenges of living with macular degeneration. Hearing how others have adapted and overcome obstacles can provide both practical tips and emotional encouragement.^[17]

Maintaining social connections becomes especially important. Isolation can lead to decreased mental health and accelerated cognitive decline. Continuing to participate in hobbies, social gatherings, and community activities might require some modifications—asking friends to meet in well-lit restaurants, requesting large-print programs at cultural events, or accepting transportation assistance—but these adaptations allow meaningful engagement to continue. Family members and friends often appreciate guidance about helpful accommodations, as they genuinely want to provide support but may not know what’s most useful.^[17]

Financial and legal planning also matters. Vision loss can affect the ability to manage medications safely, read financial documents, or drive. Addressing these practical concerns proactively—perhaps by setting up automatic bill payments, working with a financial advisor who understands vision impairment, or arranging alternative transportation—reduces stress and maintains independence. Some people with advanced vision loss may qualify for disability benefits or programs that provide assistive devices and services.^[17]

Safety modifications at home prevent falls and injuries. Good lighting throughout living spaces, removing tripping hazards like loose rugs, marking step edges with contrasting tape, and organizing belongings in consistent locations all contribute to safer navigation. Simple adaptations like using contrasting colors—a dark cutting board for light-colored vegetables, brightly colored cups that stand out against countertops—make kitchen tasks easier and safer.^[18]

Many patients report that staying informed about their condition, understanding what to expect, and actively participating in their care provides a sense of control that counters feelings of helplessness. Asking questions during medical appointments, keeping notes about vision changes, and learning about new research developments helps people feel more empowered in their journey with dry AMD.^[23]